Impact of allogeneic stem cell transplantation on survival of patients less than 65 years with primary myelofibrosis
Standard
Impact of allogeneic stem cell transplantation on survival of patients less than 65 years with primary myelofibrosis. / Kröger, Nicolaus; Giorgino, Toni; Scott, Bart L; Ditschkowski, Markus; Alchalby, Haefaa; Cervantes, Francisco; Vannucchi, Alessandro; Cazzola, Mario; Morra, Enrica; Zabelina, Tatjana; Maffioli, Margherita; Pereira, Arturo; Beelen, Dietrich; Deeg, H Joachim; Passamonti, Francesco.
In: BLOOD, Vol. 125, No. 21, 17.03.2015, p. 3347-3350.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Impact of allogeneic stem cell transplantation on survival of patients less than 65 years with primary myelofibrosis
AU - Kröger, Nicolaus
AU - Giorgino, Toni
AU - Scott, Bart L
AU - Ditschkowski, Markus
AU - Alchalby, Haefaa
AU - Cervantes, Francisco
AU - Vannucchi, Alessandro
AU - Cazzola, Mario
AU - Morra, Enrica
AU - Zabelina, Tatjana
AU - Maffioli, Margherita
AU - Pereira, Arturo
AU - Beelen, Dietrich
AU - Deeg, H Joachim
AU - Passamonti, Francesco
N1 - Copyright © 2015 American Society of Hematology.
PY - 2015/3/17
Y1 - 2015/3/17
N2 - Allogeneic hematopoietic stem cell transplantation (ASCT) is the only curative option for patients with primary myelofibrosis (PMF), but information on the net advantage over conventional therapies is lacking. Using an ad hoc statistical analysis, we determined outcomes in 438 patients younger than 65 years at diagnosis who received ASCT (n=190) or conventional therapies (n=248). Among patients with low risk by Dynamic International Prognostic Scoring System (DIPSS) prognostic model the relative risk of dying after receiving ASCT versus those treated with non-transplant modalities was 5.6 (95% CI: 1.7-19; P=0.0051); for intermediate-1 risk it was 1.6 (95% CI: 0.79-3.2; P=0.19), for intermediate-2, 0.55 (95% CI: 0.36-0.83; P=0.005), and for high risk 0.37 (95% CI: 0.21-0.66; P=0.0007). Thus, patients with intermediate-2 or high risk PMF clearly benefit from ASCT. Patients at low risk should receive non-transplant therapy, while individual counseling is indicated for patients at intermediate-1 risk.
AB - Allogeneic hematopoietic stem cell transplantation (ASCT) is the only curative option for patients with primary myelofibrosis (PMF), but information on the net advantage over conventional therapies is lacking. Using an ad hoc statistical analysis, we determined outcomes in 438 patients younger than 65 years at diagnosis who received ASCT (n=190) or conventional therapies (n=248). Among patients with low risk by Dynamic International Prognostic Scoring System (DIPSS) prognostic model the relative risk of dying after receiving ASCT versus those treated with non-transplant modalities was 5.6 (95% CI: 1.7-19; P=0.0051); for intermediate-1 risk it was 1.6 (95% CI: 0.79-3.2; P=0.19), for intermediate-2, 0.55 (95% CI: 0.36-0.83; P=0.005), and for high risk 0.37 (95% CI: 0.21-0.66; P=0.0007). Thus, patients with intermediate-2 or high risk PMF clearly benefit from ASCT. Patients at low risk should receive non-transplant therapy, while individual counseling is indicated for patients at intermediate-1 risk.
U2 - 10.1182/blood-2014-10-608315
DO - 10.1182/blood-2014-10-608315
M3 - SCORING: Journal article
C2 - 25784679
VL - 125
SP - 3347
EP - 3350
JO - BLOOD
JF - BLOOD
SN - 0006-4971
IS - 21
ER -